ASH12: Apixaban cuts risk of venous thromboembolism


Extended treatment with apixaban -- a novel blood thinner not yet approved in the United States -- reduced the risk of recurrent venous thromboembolism by approximately 80% without increasing the rate of major bleeding, according to research presented at the American Society of Hematology in Atlanta. Patrice Wendling interviewed the study's chair, Dr. Giancarlo Agnelli, to learn more about the findings.

Next Article: